Neurocysticercosis

Seminars in Neurology

Volumn 25, Issue 3, 2005, Pages 243-251

  Del Brutto, Oscar H ^a,b  

^a Air Center 3542   (United States)

^b HOSPITAL CLÍNICA KENNEDY   (Ecuador)

Author keywords

Albendazole; Cysticercosis; Helminthic infections; Neurocysticercosis; Praziquantel

Indexed keywords

ALBENDAZOLE; ANTICESTODAL AGENT; ANTICONVULSIVE AGENT; CORTICOSTEROID; DEXAMETHASONE; MANNITOL; OSMOTIC DIURETIC AGENT; PRAZIQUANTEL;

BRAIN CYST; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPING COUNTRY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; ENDEMIC DISEASE; EPILEPSY; FOOD CONTAMINATION; HELMINTHIASIS; HUMAN; HYDROCEPHALUS; IMAGE ANALYSIS; IMMIGRATION; IMMUNITY; IMMUNOLOGICAL TECHNIQUE; INDUSTRIALIZATION; INTERMEDIATE HOST; INTRACRANIAL HYPERTENSION; NEUROCYSTICERCOSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEIZURE; SYMPTOM; TAENIA SOLIUM;

ANIMALS; ANTIPLATYHELMINTIC AGENTS; BRAIN; HUMANS; NERVOUS SYSTEM; NEUROCYSTICERCOSIS; TAENIA SOLIUM; TOMOGRAPHY, X-RAY COMPUTED;

EID: 26444561038     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-917661     Document Type: Review

References (33)

1. García HH, Gonzalez AE, Evans CAW, Gilman RH. Taenia solium cysticercosis. Lancet 2003;362:547-556
2. Ong S, Talan DA, Moran GJ, et al. Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments. Emerg Infect Dis 2002;8:608-613
3. Sotelo J. Neurocysticercosis: eradication of cysticercosis is an attainable goal. BMJ 2003;326:511-512
4. Román G, Sotelo J, Del Brutto OH, et al. A proposal to declare neurocysticercosis an international reportable disease. Bull World Health Organ 2000;78:399-406
5. Del Brutto OH, Sotelo J, Roman GC. Neurocysticercosis: A Clinical Handbook. Lisse, The Netherlands: Swets & Zeitlinger; 1998
6. Pittella JEH. Neurocysticercosis. Brain Pathol 1997;7:681-693
7. Escobar A, Weidenheim KM. The pathology of neurocysticercosis. In: Singh G, Prabhakar S, eds. Taenia Solium Cysticercosis: From Basic to Clinical Science. Oxford, UK: CAB International; 2002:289-305
8. Del Brutto OH. Cysticercosis and cerebrovascular disease: a review. J Neurol Neurosurg Psychiatry 1992;55:252-254
9. Del Brutto OH, Santibañez R, Noboa CA, Aguirre R, Díaz E, Alarcón TA. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992;42:389-392
10. Estañol B, Kleriga E, Loyo M, et al. Mechanisms of hydrocephalus in cerebral cysticercosis: implications for therapy. Neurosurgery 1983;13:119-123
11. Noboa CA. Encefalitis cisticercosa. Rev Ecuat Neurol 1992;1:61-71
12. Singh G, Sawhney IS. Taenia solium cysticercosis: uncommon manifestations. In: Singh G, Prabhakar S, eds. Taenia Solium Cysticercosis: From Basic to Clinical Science. Oxford, UK: CAB International; 2002:229-239
13. Sawhney BB, Chopra JS, Banerji AK, Wahi PL. Pseudohypertrophic myopathy in cysticercosis. Neurology 1976;26: 270-272
14. García HH, Del Brutto OH. Imaging findings in neurocysticercosis. Acta Trop 2003;87:71-78
15. Ordoñez G, Medina MT, Sotelo J. Immunoblot analysis of serum and CSF from patients with various forms of neurocysticercosis. Neurol Infect Epidemiol 1996;1:57-61
16. Del Brutto OH, Rajshekhar V, White AC Jr, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology 2001; 57:177-183
17. Del Brutto OH, Sotelo J, Roman GC. Therapy for neurocysticercosis: a reappraisal. Clin Infect Dis 1993;17:730-735
18. García HH, Evans CAW, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15:747-756
19. Sotelo J, Del Brutto OH, Penagos P, et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990;237:69-72
20. Takayanagui OM, Jardim E. Therapy for neurocysticercosis: comparison between albendazole and praziquantel. Arch Neurol 1992;49:290-294
21. Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J 2003;22:268-272
22. Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004;350:249-258
23. Bittencourt PRM, Gracia CM, Gorz AM, Mazer S, Oliveira TV. High-dose praziquantel for neurocysticercosis: efficacy and tolerability. Eur Neurol 1990;30:229-234
24. Del Brutto OH, Campos X, Sánchez J, Mosquera A. Single-day praziquantel versus 1-week albendazole for neurocysticercosis. Neurology 1999;52:1079-1081
25. Garcia HH, Gilman RH, Horton J, et al. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Neurology 1997;48: 1421-1427
26. Proaño JV, Madrazo I, Avelar F, López-Félix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001;345: 879-885
27. Del Brutto OH, Sotelo J, Aguirre R, Díaz-Calderón E, Alarcón TA. Albendazole therapy for giant subarachnoid cysticerci. Arch Neurol 1992;49:535-538
28. Rajshckhar V. Solitary cerebral cysticercus granuloma. Epilepsia 2003;44(suppl 1):25-28
29. Del Brutto OH. The use of albendazole in patients with single lesions enhanced on contrast CT. N Engl J Med 1993;328: 356-357
30. Del Brutto OH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 1994;44:1706-1709
31. Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis: a long-term follow-up review of 92 cases. J Neurosurg 1987;66:686-689
32. Suastegui Roman RA, Soto-Hernández JL, Sotelo J. Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. J Neurosurg 1996;84:629-633
33. Bergsneider M, Holly LT, Lee JH, King WA, Frazee JG. Endoscopic management of cysticercal cysts within the lateral and third ventricles. J Neurosurg 2000;92:14-23